Yum! Brands, Inc. (YUM) Stock Price Today
Aura AI Summary
Key Stats
- $43.61BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $168.16FIFTY_TWO_WEEK_HIGH
- $138.21FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $54.88BENTERPRISE_VALUE
- 1.82%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Yum! Brands, Inc. (YUM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Yum! Brands, Inc. has traded between a low of $138.21 and a high of $168.16, highlighting its annual price range. Buy and sell Yum! Brands, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Most Recent News
Valterra Platinum seen as undervalued with strong 2025 EBITDA growth and strategic refining edge.
Valterra Platinum is considered undervalued because it is viewed more as a strategic, integrated platinum group metals (PGM) platform rather than a typical cyclical miner. Its 2025 adjusted EBITDA is projected to rise 68% to R33.4 billion, with margi...
Fannie Mae and Freddie Mac may exit conservatorship soon amid regulatory easing and IPO plans.
Fannie Mae and Freddie Mac, under conservatorship since 2008, are positioned for a potential exit linked to revised capital requirements. A recent executive order from former President Trump directs the FHFA to consider lowering capital requirements ...
Mirum Pharmaceuticals boosts 2026 sales forecast amid strong liver disease drug growth
Mirum Pharmaceuticals is rapidly growing as a leader in liver disease treatments, raising its 2026 global sales forecast to $660–$680 million due to strong performance of its drug LIVMARLI. Although recent acquisitions have delayed the company’s cash...